Filter Results:
(924)
Show Results For
- All HBS Web
(1,277)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,277)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Sort by
- February 1996 (Revised April 2004)
- Case
Eli Lilly and Company: Innovation in Diabetes Care
By: Clayton M. Christensen
Summarizes Eli Lilly's history of innovation in its business, describing how the dimensions along which innovations have been made in the industry have changed. Lilly's innovation strategy has been to pursue ever higher performance products, while others in the... View Details
Keywords: Change; Product; Service Delivery; Product Development; Innovation and Management; Innovation Strategy; Health Care and Treatment; Pharmaceutical Industry
Christensen, Clayton M. "Eli Lilly and Company: Innovation in Diabetes Care." Harvard Business School Case 696-077, February 1996. (Revised April 2004.)
- August 1995
- Teaching Note
Eli Lilly and Company: The Flexible Facility Decision (1993) TN
By: Gary P. Pisano
Teaching Note for (9-694-074). View Details
Keywords: Pharmaceutical Industry
- February 1987 (Revised January 1989)
- Case
SmithKline Consumer Products: The Contac Relaunch
In March 1986, a tamperer contaminated CONTAC Cold Capsules, SmithKline Consumer Product's most popular product. To relaunch CONTAC after withdrawing it from the market, the management team had to present a plan of action to the corporation board. They knew CONTAC's 25... View Details
Kosnik, Thomas J. "SmithKline Consumer Products: The Contac Relaunch." Harvard Business School Case 588-046, February 1987. (Revised January 1989.)
- February 1974
- Case
Listerine Lozenges
Greyser, Stephen A. "Listerine Lozenges." Harvard Business School Case 574-062, February 1974.
- February 1992 (Revised April 1995)
- Case
Pfizer: Global Protection of Intellectual Property
By: Lynn S. Paine and Michael Santoro
Top officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection... View Details
Keywords: Patents; Trade; Policy; Government and Politics; Business Strategy; Agreements and Arrangements; Alliances; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; United States; Japan; Europe
Paine, Lynn S., and Michael Santoro. "Pfizer: Global Protection of Intellectual Property." Harvard Business School Case 392-073, February 1992. (Revised April 1995.)
- August 1990 (Revised March 1991)
- Case
Eli Lilly and Co. (C): Japan
Describes the process of establishing an independent operation in Japan in the mid-1980s as a result of a decision to make a major investment in the market. Describes the challenges in setting up such an operation and focuses on the role of the country manager in... View Details
Keywords: Business Divisions; Business Startups; Decisions; Investment; Growth Management; Managerial Roles; Markets; Problems and Challenges; Pharmaceutical Industry; Japan
Yoshino, Michael Y. "Eli Lilly and Co. (C): Japan." Harvard Business School Case 391-034, August 1990. (Revised March 1991.)
- April 1989 (Revised January 1994)
- Case
Novo Industri
By: Michael E. Porter and Michael J. Enright
Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an... View Details
Keywords: Change; Global Strategy; Industry Structures; Alliances; Competitive Strategy; Health Disorders; Pharmaceutical Industry
Porter, Michael E., and Michael J. Enright. "Novo Industri." Harvard Business School Case 389-148, April 1989. (Revised January 1994.)
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers... View Details
Keywords: by Bill George
- 20 May 2013
- Op-Ed
Making America an Industrial Powerhouse Again
talent pool in the US biomedical field that is second to none. And the only way to get that talent is for companies-both domestic and foreign-to do their R&D here. That's why pharmaceutical and biotechnology companies from around the... View Details
- 11 May 2020
- Op-Ed
Immigration Policies Threaten American Competitiveness
It is no secret that immigration has reshaped American innovation. Immigrants are the backbone of America’s most innovative industries, provide a quarter of our patent applications, and are numerous among our science and engineering superstars. Taken from World... View Details
Keywords: by William R. Kerr
- 05 Mar 2001
- What Do You Think?
Fine Coupling: Can Human Resource Management Learn from Supply Chain Management?
Productivity will improve as the alternation of job assignments eliminates the 'indispensable' worker." Connie Luthy says, "I have practiced 'Just-In-Time' hiring ... in the pharmaceutical industry.... I have advised my client... View Details
Keywords: by James Heskett
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
challenges, not on the hard work of winning hearts and minds, Shapiro ultimately lost his company. He was forced to sell Monsanto to Pharmacia-Upjohn, which bought it for its pharmaceutical division, valuing the agricultural biotechnology... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- April 2024 (Revised November 2024)
- Case
Moderna: Pioneering a People Platform to Accelerate Science Innovation
By: Tatiana Sandino, Emil Dy and Samuel Grad
Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details
Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Pharmaceutical Industry; Pharmaceutical Industry; United States
Sandino, Tatiana, Emil Dy, and Samuel Grad. "Moderna: Pioneering a People Platform to Accelerate Science Innovation." Harvard Business School Case 124-091, April 2024. (Revised November 2024.)
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
- Article
Trends and Predictors of Biomedical Research Quality, 1990–2015: A Meta-Research Study
By: Maryaline Catillon
Keywords: Biomedical Research; R＆D; Innovation; Technology; Drug Trials; RCT; Health; Healthcare; Health Care And Treatment; Health Care Policy; Innovation and Invention; Innovation Strategy; Research and Development; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry
Catillon, Maryaline. "Trends and Predictors of Biomedical Research Quality, 1990–2015: A Meta-Research Study." BMJ Open 9, no. 9 (September 2019).
- September 2012
- Case
SCMS: Battling HIV/AIDS in Africa
By: Ananth Raman, Noel Watson, Santiago Kraiselburd and Emmanuel Akili
In 2005, USAID and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), created the Supply Chain Management System (SCMS) to procure and distribute essential medicines and supplies; provide technical assistance to transform existing supply chains; and... View Details
Keywords: HIV; AIDS; Procurement Coordination; Developing Countries; Healthcare; Public Health; Ethiopia; Supply Systems For Healthcare Delivery In Developing Countries; Healthcare Logistics Industry; Health Disorders; Health Care and Treatment; Service Delivery; Supply Chain Management; Logistics; Developing Countries and Economies; Programs; Transition; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Ethiopia; Africa
Raman, Ananth, Noel Watson, Santiago Kraiselburd, and Emmanuel Akili. "SCMS: Battling HIV/AIDS in Africa." Harvard Business School Case 613-023, September 2012.
- February 2010
- Background Note
Millipore Background Note
By: Elie Ofek and Natalie Kindred
This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details
Keywords: Organizational Change and Adaptation; Customer Focus and Relationships; Pharmaceutical Industry; Pharmaceutical Industry
Ofek, Elie, and Natalie Kindred. "Millipore Background Note." Harvard Business School Background Note 510-059, February 2010.
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- Article
A Blueprint for Pharmacy Benefits Managers to Increase Value
By: William Shrank, Michael E. Porter, Sachin H. Jain and Niteesh K. Choudhary
Pharmacy benefits managers (PBMs) have a unique opportunity to promote public health and generate value in the healthcare system. However, PBMs are largely evaluated on their ability to control costs rather than improve health. PBMs should be evaluated along three... View Details
Keywords: Opportunities; Health; System; Cost Management; Partners and Partnerships; Motivation and Incentives; Value; Innovation and Invention; Performance Effectiveness; Pharmaceutical Industry; Pharmaceutical Industry
Shrank, William, Michael E. Porter, Sachin H. Jain, and Niteesh K. Choudhary. "A Blueprint for Pharmacy Benefits Managers to Increase Value." American Journal of Managed Care 15, no. 2 (February 2009).
- April 1989
- Supplement
Novel Combination of Two Drugs (C)
Herzlinger, Regina E. "Novel Combination of Two Drugs (C)." Harvard Business School Supplement 189-170, April 1989.